Klinsel

Klinsel

Seoul, South Korea· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Klinsel, established in 2009, is a private limited company and a leading local CRO in Malaysia, offering end-to-end clinical trial management services. The company has extensive experience in conducting international and local studies, with a strong network of clinicians and hospitals. Klinsel's mission is to ensure clinical research projects are conducted with the highest standards, on par with international best practices, while adhering to local guidelines and regulatory requirements. The company is well-positioned to serve as a partner for global studies requiring subject recruitment in Malaysia.

OncologyNephrologyOrthopedicsCardiovascularRespiratoryPsychiatryStem CellOphthalmology

Technology Platform

Comprehensive clinical trial management services including site management, patient recruitment, regulatory compliance, and project management for Phase II-IV studies.

Opportunities

Klinsel can capitalize on the growing trend of pharmaceutical companies outsourcing clinical trials to emerging markets, leveraging its local expertise and government recognition to attract more international sponsors.
Expansion into additional therapeutic areas and offering specialized services such as bioanalytical lab support could further drive growth.

Risk Factors

Klinsel faces competition from larger global CROs with more resources and broader geographic reach.
Regulatory changes in Malaysia or shifts in pharmaceutical R&D spending could impact demand for its services.
The company's reliance on a limited number of key personnel and sites may also pose operational risks.

Competitive Landscape

Klinsel competes with global CROs like IQVIA, Parexel, and PPD, as well as regional and local CROs in Southeast Asia. Its differentiation lies in its deep local knowledge, established network of Malaysian sites and investigators, and Bionexus status, which provides a stamp of government approval and support.